Yu WY, Lu B, Tan D, et al. - A randomized clinical trial was designed to ascertain whether brimonidine gel, 0.33%, decreases facial erythema in patients with alcohol flushing syndrome (AFS) after consumption of alcohol. This study included a total of 20 healthy volunteers of East Asian descent with a self-reported history of AFS between April 2018 and March 2019. The individual's mean (SD) age was 30.5 (8.4) years, and there were 10 women (50%). Individuals were assigned randomly to the application of brimonidine gel to either the left or right half of their face. They used placebo control to the opposite side. The brimonidine gel was found to be effective in decreasing the facial erythema of AFS. It was demonstrated that individuals with psychosocial distress due to AFS may benefit from treatment with brimonidine.